Understanding CYP3A4 and P‐gp mediated drug–drug interactions through PBPK modeling – Case example of pralsetinib
CPT: Pharmacometrics & Systems Pharmacology · 2024-04 · 13 (4) · 660-672
DOI: 10.1002/psp4.13114 ↗Kurz gefasst
Fachartikel in der Zeitschrift CPT: Pharmacometrics & Systems Pharmacology, online erschienen am 13.03.2024. Verfasst von Christine Bowman und 7 weiteren Autor:innen. Beteiligte Einrichtung: Genentech, Inc., South San Francisco, California, USA. Hauptthemen laut MEDLINE: Cytochrome P-450 CYP3A, Pyrimidines, Pyrazoles. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Pralsetinib, a potent and selective inhibitor of oncogenic RET fusion and RET mutant proteins, is a substrate of the drug metabolizing enzyme CYP3A4 and a substrate of the efflux transporter P‐gp based on in vitro data. Therefore, its pharmacokinetics (PKs) may be affected by co‐administration of potent CYP3A4 inhibitors and inducers, P‐gp inhibitors, and combined CYP3A4 and P‐gp inhibitors. With the frequent overlap between CYP3A4 and P‐gp substrates/inhibitors, pralsetinib is a challenging and representative example of the need to more quantitatively characterize transporter‐enzyme interplay. A physiologically‐based PK (PBPK) model for pralsetinib was developed to understand the victim drug–drug interaction (DDI) risk for pralsetinib. The key parameters driving the magnitude of pralsetinib DDIs, the P‐gp intrinsic clearance and the fraction metabolized by CYP3A4, were determined from PBPK simulations that best captured observed DDIs from three clinical studies. Sensitivity analyses and scenario simulations were also conducted to ensure these key parameters were determined with sound mechanistic rationale based on current knowledge, including the worst‐case scenarios. The verified pralsetinib PBPK model was then applied to predict the effect of other inhibitors and inducers on the PKs of pralsetinib. This work highlights the challenges in understanding DDIs when enzyme‐transporter interplay occurs, and demonstrates an important strategy for differentiating enzyme/transporter contributions to enable PBPK predictions for untested scenarios and to inform labeling.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Genentech, Inc., South San Francisco, California, USA.
ORCID-Profile: Christine Bowman, Michael Dolton, Fang Ma, Sravanthi Cheeti, Denison Kuruvilla, Rucha Sane, Nastya Kassir, Yuan Chen
Zitieren
APA
Bowman, C., Dolton, M., Ma, F., Cheeti, S., Kuruvilla, D., Sane, R., Kassir, N., & Chen, Y. (2024). Understanding CYP3A4 and P‐gp mediated drug–drug interactions through PBPK modeling – Case example of pralsetinib. CPT: Pharmacometrics & Systems Pharmacology, 13(4), 660-672. https://doi.org/10.1002/psp4.13114
Vancouver
Bowman C, Dolton M, Ma F, Cheeti S, Kuruvilla D, Sane R, et al. Understanding CYP3A4 and P‐gp mediated drug–drug interactions through PBPK modeling – Case example of pralsetinib. CPT: Pharmacometrics & Systems Pharmacology. 2024;13(4):660-672. doi:10.1002/psp4.13114
BibTeX
@article{Bowman2024,
author = {Bowman, Christine and Dolton, Michael and Ma, Fang and Cheeti, Sravanthi and Kuruvilla, Denison and Sane, Rucha and Kassir, Nastya and Chen, Yuan},
title = {Understanding CYP3A4 and P‐gp mediated drug–drug interactions through PBPK modeling – Case example of pralsetinib},
journal = {CPT: Pharmacometrics & Systems Pharmacology},
year = {2024},
volume = {13},
number = {4},
pages = {660--672},
doi = {10.1002/psp4.13114}
}
EUVIMED